Acetazolamide Capsules and Oxilan

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Before you undergo any imaging procedure where ioxilan may be given by injection, let your doctor know if you are currently being treated with acetaZOLAMIDE. Injection of ioxilan can sometimes cause kidney problems, and the risk may be increased if you are also using acetaZOLAMIDE. The interaction may be more likely if you have preexisting kidney disease, congestive heart failure, or diabetes; or if you are elderly, dehydrated, or taking other medications that can affect the kidney. Depending on your health situation, your doctor may want you to stop using acetaZOLAMIDE for a certain length of time before and after the procedure. You may also be asked to increase your fluid intake the day before the procedure, or you may be given intravenous fluids before, during, and after the procedure. Since ioxilan contains iodine, also let your doctor know if you have had a previous reaction to iodine or iodine-containing products. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy. Patients considered at high risk include those with diabetes (especially diabetic nephropathy), preexisting renal insufficiency (serum creatinine >1.5 mg/dL or GFR 70 years), congestive heart failure, and/or concurrent use of nephrotoxic drugs (e.g., NSAIDs). Diuretics have been studied for use in the prevention of contrast-induced nephropathy because investigators theorized that they may reduce medullary ischemia by decreasing oxygen demands. In published studies, however, maintenance intravenous fluids plus forced diuresis with furosemide, mannitol, or a combination of both given at the time of radiocontrast exposure generally produced similar or even higher rates of nephropathy compared with intravenous fluids alone. Meta-analyses of published data suggest that furosemide-based interventions significantly increase the risk of contrast-induced nephropathy compared with hydration alone, and one study found that hospitalization for all patients who developed contrast-induced nephropathy was increased by 4 days in those who received concomitant diuretic therapy. Contrast-induced nephropathy is most commonly defined as an increase in serum creatinine >=0.5 mg/dL or 25% from baseline within 48 to 72 hours of intravascular contrast administration in the absence of alternative etiologies, although nephropathy may occur up to a week after contrast exposure. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.

MANAGEMENT: Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.

Acetazolamide Capsules

Generic Name: acetazolamide

Brand name: Diamox, Diamox Sequels

Synonyms: Acetazolamide, AcetaZOLAMIDE

What is Acetazolamide Capsules?

Oxilan

Generic Name: ioxilan

Brand name:

Synonyms: n.a.

What is Oxilan?